Search

Your search keyword '"Ponzoni, M."' showing total 1,374 results

Search Constraints

Start Over You searched for: Author "Ponzoni, M." Remove constraint Author: "Ponzoni, M."
1,374 results on '"Ponzoni, M."'

Search Results

56. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion

61. TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantation

64. Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations

72. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

73. Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations

74. TdT expression in germ cell tumours: a possible immunohistochemical cross-reaction and diagnostic pitfall

79. INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL

80. LONG-TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)

81. R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL

82. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY

83. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

84. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

86. Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

87. NY-ESO-1 TCR single edited t cells to treat multiple myeloma without inducing GvHD

88. Single Chain TCR Gene Editing in Adoptive Cell Therapy for Multiple Myeloma

89. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3d surrogate microenvironment

90. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma

93. Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation

94. Antigen Drive in the Natural History of Mantle Cell Lymphoma: Molecular Evidence

95. Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation

96. MYELOID SARCOMA: CLINICAL FEATURES AND OUTCOMES AFTER INTENSIVE TREATMENT, TEN YEARS EXPERIENCE AT A SINGLE CENTRE

97. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

98. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

99. Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial

100. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion

Catalog

Books, media, physical & digital resources